Evidence map›Paper›PMID 27431047›Full record

ArticleJournal of substance abuse treatment2016

Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.

Michael D Stein, Mitika Kanabar, Bradley J Anderson, Anna Lembke, Genie L Bailey

Abstract read
In one paragraph

Article in Journal of substance abuse treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Initial validation of the expectancies for Benzodiazepine Analgesia Scale.Experimental and clinical psychopharmacology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Validation of theSubstance use & misuse · 2022
    Article
  17. Article
  18. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities.Translational research : the journal of laboratory and clinical medicine · 2021
    Review
  19. A Novel Maintenance Therapeutic for Opioid Use Disorder.The Journal of pharmacology and experimental therapeutics · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Michael D SteinBehavioral Medicine Division, Butler Hospital, Providence, RI, 02906, USA; Warren Alpert Medical School of Brown University, Providence, RI, 02912, USA. Electronic address: Michael_Stein@brown.edu.
Mitika KanabarStanford University School of Medicine, Stanford, CA, 94305, USA.
Bradley J AndersonBehavioral Medicine Division, Butler Hospital, Providence, RI, 02906, USA.
Anna LembkeStanford University School of Medicine, Stanford, CA, 94305, USA.
Genie L BaileyWarren Alpert Medical School of Brown University, Providence, RI, 02912, USA; Stanley Street Treatment and Resources, Inc., Fall River, MA 02720, USA.
Stanford University · USBrown University · USButler Hospital · USStanley Street Treatment and Resources · US

Funding

Advancing Clinical Research Training within Addiction Residency ProgramsR25DA033211 · NIDA · BOSTON MEDICAL CENTER · PI Patrick O'Connor, JEFFREY H. SAMET · 2012 to 2026
$4.2M
Linking Opioid Dependent Patients from Inpatient Detoxification to Primary CareR01DA034261 · NIDA · BUTLER HOSPITAL (PROVIDENCE, RI) · PI BAILEY, GENIE, STEIN, MICHAEL D · 2012 to 2016
$2.4M
NIDA NIH HHS R01 DA034261NIDA NIH HHS R25 DA033211
6 · The paper itself

Abstract

backgroundOver the past decade, patients admitted to addiction treatment programs have reported increasing rates of concurrent opioid and benzodiazepine (BZD) use. This drug combination places individuals at high risk for accidental overdose. Little is known about reasons for BZD use among individuals seeking treatment for opioid use disorders.

methodsWe surveyed consecutive persons initiating inpatient opioid detoxification and identified 176 out of 438 who reported BZD use in the past 30 days and/or had a positive toxicology.

resultsForty percent of persons surveyed used a BZD in the month prior to admission, and 25% of these met criteria for BZD dependence (DSM IV). BZD users averaged 32.0 years of age, 63.6% were male, 85.2% used heroin, and reported, on average, 13.3 (±11.2) days of BZD use during the past month. Alprazolam (Xanax) was the most commonly used BZD (52%), and buying it on the street the most common source (48%). The most commonly reported reason for BZD use was 'to manage anxiety' (42.6%), followed by 'to get or enhance a high' (27.7%), 'to help with sleep' (11.4%), and 'to decrease opioid withdrawal' (10.2%). The most common reason for BZD use was significantly associated (p<.001) with most likely source of BZDs, with persons who got their BZDs from a prescriber (23%) more likely to report BZD anxiety as their primary reason for use, while persons who bought BZDs on "the street" (48%) had the highest likelihood of reporting using BZD to get or enhance a high. Participants using BZDs most commonly for anxiety did not endorse lower anxiety than those using BZDs for other reasons.

conclusionsTwo in five persons seeking detoxification for an opioid use disorder used a BZD in the prior month. Anxiety was the most common reason patients reported using a benzodiazepine, but they also reported using BZDs to enhance a 'high' and manage opioid withdrawal. Evidence-based discussions about the risks of combining BZDs and opioids, and alternatives to BZDs should be a high priority in detoxification settings.

Indexed as

Substance Withdrawal SyndromeAdultAnxietyBenzodiazepinesFemaleHeroin DependenceHumansHypnotics and SedativesMaleOpioid-Related DisordersSubstance-Related DisordersSurveys and QuestionnairesYoung AdultBenzodiazepinesHypnotics and SedativesAnxietyBenzodiazepineDetoxificationOpioidsReasons for use

Identifiers

PMID27431047
PMCPMC4955948
OpenAlexW2426516518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.